MX2020013004A - Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. - Google Patents
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.Info
- Publication number
- MX2020013004A MX2020013004A MX2020013004A MX2020013004A MX2020013004A MX 2020013004 A MX2020013004 A MX 2020013004A MX 2020013004 A MX2020013004 A MX 2020013004A MX 2020013004 A MX2020013004 A MX 2020013004A MX 2020013004 A MX2020013004 A MX 2020013004A
- Authority
- MX
- Mexico
- Prior art keywords
- vmat2 inhibitor
- compositions
- inhibitor compounds
- methods relating
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan métodos para tratar trastornos psiquiátricos relacionados con el síndrome de supresión 22q11.2 y para seleccionar sujetos para tratamiento con un inhibidor de VMAT2. Los métodos proporcionados en la presente comprenden administrar un inhibidor de VMAT2 a un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684935P | 2018-06-14 | 2018-06-14 | |
PCT/US2019/037046 WO2019241555A1 (en) | 2018-06-14 | 2019-06-13 | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013004A true MX2020013004A (es) | 2021-02-17 |
Family
ID=67263041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013004A MX2020013004A (es) | 2018-06-14 | 2019-06-13 | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3806856A1 (es) |
JP (1) | JP2021528386A (es) |
KR (1) | KR20210021006A (es) |
CN (1) | CN112638387A (es) |
AU (1) | AU2019287524A1 (es) |
BR (1) | BR112020024018A2 (es) |
CA (1) | CA3100694A1 (es) |
EA (1) | EA202092750A1 (es) |
IL (1) | IL278758A (es) |
JO (1) | JOP20200298A1 (es) |
MA (1) | MA52896A (es) |
MX (1) | MX2020013004A (es) |
PH (1) | PH12020552088A1 (es) |
SG (1) | SG11202011544UA (es) |
TW (1) | TW202011963A (es) |
WO (1) | WO2019241555A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180075591A (ko) | 2015-10-30 | 2018-07-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 발베나진 염 및 그의 다형체 |
HUE059065T2 (hu) | 2015-12-23 | 2022-10-28 | Neurocrine Biosciences Inc | Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására |
CA3051832A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
TW201919622A (zh) | 2017-09-21 | 2019-06-01 | 美商紐羅克里生物科學有限公司 | 高劑量戊苯那嗪(valbenazine)調配物及組合物、方法以及相關套組 |
EA202090932A1 (ru) | 2017-10-10 | 2021-05-20 | Нейрокрин Байосайенсиз, Инк | Способы введения некоторых vmat2-ингибиторов |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
WO2023076568A1 (en) * | 2021-10-29 | 2023-05-04 | Neurocrine Biosciences, Inc. | Valbenazine compositions |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
NZ334914A (en) | 1996-10-01 | 2000-09-29 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
EP1313473A2 (en) | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
CA2668689C (en) * | 2006-11-08 | 2015-12-29 | Neurocrine Biosciences Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
EP2464340A2 (en) | 2009-08-12 | 2012-06-20 | Valeant International (Barbados) SRL | Pharmaceutical compositions with tetrabenazine |
US8782398B2 (en) | 2012-06-26 | 2014-07-15 | Intel Corporation | Secure user presence detection and authentication |
IN2015DN01662A (es) | 2012-09-18 | 2015-07-03 | Auspex Pharmaceuticals Inc | |
CN113413385A (zh) | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
IL248745B (en) | 2014-05-06 | 2022-07-01 | Neurocrine Biosciences | (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza |
ES2960717T3 (es) * | 2015-02-06 | 2024-03-06 | Neurocrine Biosciences Inc | [9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo |
MX2017017015A (es) | 2015-06-23 | 2018-02-26 | Neurocrine Biosciences Inc | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. |
JP2020500875A (ja) | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
AU2018241940B2 (en) | 2017-04-01 | 2023-09-28 | Adeptio Pharmaceuticals Limited | Dihydrotetrabenazine for use in the treatment a movement disorder |
CA3057543A1 (en) | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
TW201919622A (zh) | 2017-09-21 | 2019-06-01 | 美商紐羅克里生物科學有限公司 | 高劑量戊苯那嗪(valbenazine)調配物及組合物、方法以及相關套組 |
-
2019
- 2019-06-13 SG SG11202011544UA patent/SG11202011544UA/en unknown
- 2019-06-13 MA MA052896A patent/MA52896A/fr unknown
- 2019-06-13 JP JP2020568772A patent/JP2021528386A/ja active Pending
- 2019-06-13 CA CA3100694A patent/CA3100694A1/en active Pending
- 2019-06-13 KR KR1020217000734A patent/KR20210021006A/ko unknown
- 2019-06-13 MX MX2020013004A patent/MX2020013004A/es unknown
- 2019-06-13 TW TW108120550A patent/TW202011963A/zh unknown
- 2019-06-13 EP EP19739758.1A patent/EP3806856A1/en active Pending
- 2019-06-13 BR BR112020024018-4A patent/BR112020024018A2/pt unknown
- 2019-06-13 AU AU2019287524A patent/AU2019287524A1/en active Pending
- 2019-06-13 CN CN201980039832.5A patent/CN112638387A/zh active Pending
- 2019-06-13 WO PCT/US2019/037046 patent/WO2019241555A1/en active Application Filing
- 2019-06-13 EA EA202092750A patent/EA202092750A1/ru unknown
- 2019-06-13 JO JOP/2020/0298A patent/JOP20200298A1/ar unknown
-
2020
- 2020-11-17 IL IL278758A patent/IL278758A/en unknown
- 2020-12-04 PH PH12020552088A patent/PH12020552088A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019287524A1 (en) | 2020-12-24 |
PH12020552088A1 (en) | 2021-08-02 |
EP3806856A1 (en) | 2021-04-21 |
IL278758A (en) | 2021-01-31 |
WO2019241555A1 (en) | 2019-12-19 |
KR20210021006A (ko) | 2021-02-24 |
TW202011963A (zh) | 2020-04-01 |
JOP20200298A1 (ar) | 2020-11-22 |
CA3100694A1 (en) | 2019-12-19 |
MA52896A (fr) | 2021-04-21 |
JP2021528386A (ja) | 2021-10-21 |
EA202092750A1 (ru) | 2021-05-13 |
CN112638387A (zh) | 2021-04-09 |
SG11202011544UA (en) | 2020-12-30 |
BR112020024018A2 (pt) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
AR126205A2 (es) | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
MX2021005529A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp. | |
MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
EP4219718A3 (en) | Compositions and methods for modulating complement factor b expression | |
EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
GEP20186876B (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
MX2020010908A (es) | Composiciones infundidas con compuestos de nicotina y metodos de uso de las mismas. | |
NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
WO2018127612A3 (en) | Compositions comprising lespedeza plant extract | |
PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2021006463A (es) | Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3. | |
MX2021012634A (es) | Neurogénesis. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
ZA201907101B (en) | Methods of preventing or treating ophthalmic diseases | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
MX2021000601A (es) | Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma. |